Results of a Phase I-II Study of Fenretinide and Rituximab for Patients with Indolent B-Cell Lymphoma and Mantle Cell Lymphoma

Fenretinide, a synthetic retinoid, induces apoptotic cell death in B-cell non-Hodgkin lymphoma (B-NHL) and acts synergistically with rituximab in preclinical models. We report results from a phase I–II study of fenretinide with rituximab for B-NHLs. Eligible diagnoses included indolent B-NHL or mant...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Haematol
Main Authors: Cowan, Andrew J., Stevenson, Phillip A., Gooley, Ted A., Frayo, Shani L., Oliveira, George R., Smith, Stephen D., Green, Damian J., Roden, Jennifer E., Pagel, John M., Wood, Brent L., Press, Oliver W., Gopal, Ajay K.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5303179/
https://ncbi.nlm.nih.gov/pubmed/28055107
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.14451
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados